TITLE

Nephrology/pediatric nephrology

PUB. DATE
August 1997
SOURCE
Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS68
SOURCE TYPE
Academic Journal
DOC. TYPE
Abstract
ABSTRACT
Presents an abstract of the research manuscript `Current practices and outcomes in BC dialysis PTS: Focus on calcium phosphate and parathroid hormone (IPTH) outcomes,' by S. Singh et al.
ACCESSION #
9708236810

 

Related Articles

  • Reply from the authors. Monier-Faugere, Marie-Claude; Malluche, Hartmut H. // Kidney International;Mar2002, Vol. 61 Issue 3, p1181 

    Presents the reply to correspondence on the value of the parathyroid hormone (1-84) PTH/C-PTH ratio for the diagnosis of low bone turnover in dialysis patients. Treatment response of bone turnover to vitamin D; Association of vitamin D therapy in patients with adynamic bone disease with...

  • Cinacalcet is efficacious in pediatric dialysis patients. Silverstein, Douglas M.; Kher, Kanwal K.; Moudgil, Asha; Khurana, Mona; Wilcox, Jennifer; Moylan, Kathleen // Pediatric Nephrology;Oct2008, Vol. 23 Issue 10, p1817 

    Secondary hyperparathyroidism (high-turnover bone disease, or HTBD) is manifested by elevated parathyroid hormone (PTH) levels. Control of HTBD may be achieved by maintaining low serum phosphorous levels and administering vitamin D therapy, although some patients continue to exhibit high PTH...

  • Achieving NKF-K/DOQIâ„¢ bone metabolism and disease treatment goals with cinacalcet HCl. Moe, Sharon M.; Chertow, Glenn M.; Coburn, Jack W.; Quarles, L. Darryl; Goodman, William G.; Block, Geoffrey A.; Drüeke, Tilman B.; Cunningham, John; Sherrard, Donald J.; McCary, Laura C.; Olson, Kurt A.; Turner, Stewart A.; Martin, Kevin J. // Kidney International;Feb2005, Vol. 67 Issue 2, p760 

    Achieving NKF-K/DOQIâ„¢ bone metabolism and disease treatment goals with cinacalcet HCl.Background.The National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (NKF-K/DOQIâ„¢) has established guidelines for treatment of secondary hyperparathyroidism (HPT). The ability of...

  • Disturbed mineral metabolism is associated with muscle and skin complaints in a prospective cohort of dialysis patients. Marlies Noordzij; Elisabeth W. Boeschoten; Willem J. Bos; Friedo W. Dekker; Patrick M. Bossuyt; Raymond T. Krediet; Johanna C. Korevaar; for the NECOSAD Study Group // Nephrology Dialysis Transplantation;Oct2007, Vol. 22 Issue 10, p2944 

    Background. Disturbed mineral metabolism is associated with increased morbidity and mortality, however, its influence on physical symptoms is less clear. We explored the effects of disordered plasma calcium, phosphorus, calcium-phosphorus (Ca × P) product and intact parathyroid hormone...

  • Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism. Ureña-Torres, Pablo; Bridges, Ian; Christiano, Cynthia; Cournoyer, Serge H.; Cooper, Kerry; Farouk, Mourad; Kopyt, Nelson P.; Rodriguez, Mariano; Zehnder, Daniel; Covic, Adrian // Nephrology Dialysis Transplantation;May2013, Vol. 28 Issue 5, p1241 

    Background Treatment with cinacalcet improves the control of secondary hyperparathyroidism (SHPT) and the achievement of calcium and phosphorus targets. Most data come from subjects receiving cinacalcet after several years of dialysis treatment. We therefore compared the efficacy of treatment...

  • Long-term control of parathyroid hormone and calcium-phosphate metabolism after parathyroidectomy in children with chronic kidney disease. Schaefer, Betti; Schlosser, Katja; Wühl, Elke; Schall, Petra; Klaus, Günter; Schaefer, Franz; Schmitt, Claus Peter // Nephrology Dialysis Transplantation;Aug2010, Vol. 25 Issue 8, p2590 

    Background. Hyperparathyroidism (HPT) is an essential contributor to bone disease and cardiovascular calcifications in children with chronic kidney disease (CKD). Pharmacological and dietary interventions are of limited efficacy; calcimimetics are not yet recommended in children....

  • False low parathyroid hormone values secondary to sample contamination with the tissue plasminogen activator. Schiller, Brigitte; Wong, Amy; Blair, Marty; Moran, John // Nephrology Dialysis Transplantation;Jul2009, Vol. 24 Issue 7, p2240 

    Background. Fluctuating parathyroid hormone values (PTH) are common in patients undergoing haemodialysis. Widely varying PTH results in an 82-year-old haemodialysis (HD) patient could not be explained. When PTH in the same blood sample was no longer detectable 24 h after blood draw, it was...

  • Abstracts.  // Kidney International;Dec1977, Vol. 12 Issue 6, p453 

    The article presents abstracts of several articles on kidney diseases. The paper "Search for the Uremic Toxin: Parathormone Levels and Nerve Conduction in Man," by Morell M. Avram, Donald A. Feinfeld, and Aibar H. Huatco, assesses the role of parathormone (PTH) as uremic toxin. They studied...

  • Influence of dialysate calcium concentration and vitamin D on serum parathyroid hormone during repetitive dialysis. Bouillon, Roger; Verberckmoes, René; de Moor, Pieter // Kidney International;Jan1975, Vol. 7 Issue 1, p422 

    An acute rise or decrease in parathyroid hormone (PTH) secretion was found in 30 patients, dialyzed with, respectively, low (5 mg/100 ml) or high (7.5 mg/100 ml) calcium concentration. The percentage changes were, respectively, +35% and -47% when a N-terminal antiserum measuring predominantly...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics